%0 Journal Article
%T The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
%A Li Wang
%A Qian Yang
%A Shaoyong Peng
%A Xiaoxia Liu
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S212465
%X Chemotherapy remains a major clinical option for the successful treatment of cancer by eliminating fast-growing populations of cancer cells. However, drug resistance causes the failure of antitumor treatment. Increasing evidence suggests that a small subpopulation of cancer cells will enter a ¡°persister state¡± under drug pressure. The persister cell pool constitutes a reservoir from which drug resistance may emerge. Therefore, targeting persister cells presents a therapeutic opportunity to prevent drug resistance and impede tumor relapse
%K persister cells
%K drug-resistance
%K sorafenib
%K glycolysis inhibitor
%K antitumor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635829/